Indication
Refractory Central Nervous System Tumor
1 clinical trial
1 product
Product
CemiplimabClinical trial
A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients With Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade GliomaStatus: Terminated, Estimated PCD: 2023-05-10